Texas Busi­ness Di­gest:

Austin American-Statesman - - BUSINESS -

Sam­sung re­ports higher op­er­at­ing profit; Molec­u­lar Tem­plates inks can­cer-drug pact with Eli Lilly unit

Ge­orge­town-based Molec­u­lar Tem­plates Inc. has signed a deal with ImClone Sys­tems Inc., a sub­sidiary of Eli Lilly & Co., to col­lab­o­rate on re­search­ing and de­vel­op­ing can­cer drugs.

The work will in­volve en­gi­neered toxin bod­ies, or ETBs, which are mod­i­fied bac­te­rial tox­ins that have shown prom­ise as tar­geted treat­ments for can­cer, killing only spe­cific cells. Molec­u­lar Tem­plates has de­vel­oped a li­brary of ETBs that can be screened as po­ten­tial anti-can­cer agents.

Molec­u­lar Tem­plates re­ceived $2.5 mil­lion in ven­ture fund­ing last year in a round led by Sante Ven­tures in Austin. The com­pany was founded in Canada but moved its head­quar­ters last year to the Texas Life-Sci­ences Col­lab­o­ra­tion Cen­ter in Ge­orge­town, which pro­vides wet-lab space for biotech star­tups.

Newspapers in English

Newspapers from USA

© PressReader. All rights reserved.